Literature DB >> 8564411

Synthesis and evaluation of pyrazolignans. A new class of cytotoxic agents.

M Gordaliza1, J M del Corral, M A Castro, M L López-Vázquez, A San Feliciano, M D García-Grávalos, A Carpy.   

Abstract

A series of fused pyrazole derivatives of cyclolignans have been prepared through simple chemical routes and evaluated for their cytotoxic activities in culture cells of P-388 murine leukemia, A-549 lung carcinoma and HT-29 colon carcinoma. Despite the lack of the lactone moiety in their structures, they show IC50 values at microM levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564411     DOI: 10.1016/0968-0896(95)00091-t

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

Review 1.  Natural products as leads to anticancer drugs.

Authors:  M Gordaliza
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

2.  Molecular modelling evaluation of the cytotoxic activity of podophyllotoxin analogues.

Authors:  Md Afroz Alam; Pradeep Kumar Naik
Journal:  J Comput Aided Mol Des       Date:  2008-12-04       Impact factor: 3.686

Review 3.  Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents.

Authors:  Ying-Qian Liu; Jing Tian; Keduo Qian; Xiao-Bo Zhao; Susan L Morris-Natschke; Liu Yang; Xiang Nan; Xuan Tian; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2014-05-14       Impact factor: 12.944

4.  MEDT study of the 1,3-DC reaction of diazomethane with Psilostachyin and investigation about the interactions of some pyrazoline derivatives with protease (Mpro) of nCoV-2.

Authors:  M Salah; M E Belghiti; A O Aitouna; A Zeroual; S Jorio; H El Alaoui Abdellaoui; H El Hadki; K Marakchi; N Komiha
Journal:  J Mol Graph Model       Date:  2020-09-24       Impact factor: 2.518

Review 5.  Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview.

Authors:  Dimitris Matiadis; Marina Sagnou
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.